Experts highlight key data to help you learn what to expect at the upcoming Hematology meeting in Orlando. The CCO Conference Coverage program will feature downloadable slides and expert commentaries of clinically relevant studies presented at ASH 2019. We will have the information you need to understand and integrate the latest hematology data into your practice.
Review the most clinically relevant data in leukemias, lymphomas, MDS, MPNs, multiple myeloma, and nonmalignant hematologic disorders presented at the 2019 ASH Annual Meeting.
Get expert perspective on the key studies in AML and ALL from ASH 2019 that may impact your practice and help you to improve patient outcomes.
Are you aware of the latest clinical data in CLL and lymphomas? In this commentary, Jeff P. Sharman, MD, discusses 5 key studies on CLL/lymphomas that were recently presented at ASH 2019.
In this commentary, Rami S. Komrokji, MD, provides an overview of key MDS and MPN studies from ASH 2019.
Did you see the latest clinical data in myeloma? In this commentary, Sagar Lonial, MD, discusses the key studies on myeloma that were recently presented at ASH 2019.
In this commentary, Hanny Al-Samkari, MD, and Sujit Sheth, MD, provide insights on key studies in nonmalignant hematologic disorders presented at ASH 2019.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.